home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  

registry of biomedical companies

  July 16, 2024
promoting the transfer of scientific know-how between industry and academia
Registry of biomedical companies:

[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 456 active entries

Oryzon Genomics S.A.

Sant Ferran 74
Cornella de Llobregat E-08940

Phone: + 34 93 515 1313
Fax: + 34 93 377 40 28

Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.



Oryzon is the first Spanish biomarker and target discovery company in cancer and neurodegenerative disorders. The mission of the company is to identify new genes and proteins so as to design and develop biotechnological products that improve people’s health. The R&D pipeline is focused on preventive health programs with early diagnostics and new therapies in cancer and neurological disorders. The company is venture backed with a very robust financial status supporting R&D operations.


ORYZON genomics is a biopharmaceutical company based in Barcelona, and focused on the exploitation of biomarkers identified through genomics and proteomics in three fields: DIAGNOSTICS, PERSONALIZED MEDICINE and THERAPY.

In DIAGNOSTICS AND PERSONALIZED MEDICINE, our strategy is to market our products and services directly in Spain and the South of Europe through our ORYZONDX portal, which will be launched in Q4 2011. Our product pipeline contains both products that were developed inside the company like GynEC®-DX or ColoBRAF™, and selected in-licensed products that fit in our business model like Cxbladder®.

ORYZON has been accredited and registered with the status of Clinical Genetic Laboratory by the General Directorate of Sanitary Resources of Catalonia.

At the international level, we look for global or regional partners that can commercialize our products in a fast and efficient manner.

In THERAPY, our business model is the development of NCEs and monoclonal antibodies directed against novel targets identified in our biomarker discovery programs in the fields of NEURODEGENERATION and CANCER.

We use genomic technologies for the identification and definition of biomarkers. A number of these markers can be directly related to the development process of complex diseases such as cancer and neurodegenerative diseases. These are pharmacological targets.

Depending on the characteristics of these targets, ORYZON uses its fragment-screening technology, crystallography and molecular modeling to develop small molecules in DRUG DISCOVERY programs, or use its phage-display technology to develop MONOCLONAL ANTIBODIES.

In the field of small molecules, ORYZON had specialized in EPIGENETIC TARGETS.

In the field of monoclonal antibodies, ORYZON has specialized in novel targets.

Our pipeline is preclinical and we aim to reach the clinical phase in 2012.

We have generated a broad patent portfolio to protect our developments and are willing to consider out-licensing to experienced companies that can accelerate the preclinical and clinical development of our drugs for different indications.

Technology and services

We have a long tradition to collaborate with pharma and agrofood industry offering advanced R&D services including: genomic and proteomic analysis, bioinformatics, biomarker and target validation, crystallography and molecular modeling, fragment screening and a wide range of biological assays. Our ISO9001 quality system is the best guarantee for the quality of our services.

Selected Categories:
Product Company   Service Company
- Research
- Research
- in vitro
- Medical
- Research
- Research
- Services

Last update of this entry: October 25, 2011

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2024 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.